{"id":36331,"date":"2025-07-22T15:13:02","date_gmt":"2025-07-22T12:13:02","guid":{"rendered":"https:\/\/massivebio.com\/?p=36331"},"modified":"2025-07-22T15:13:02","modified_gmt":"2025-07-22T12:13:02","slug":"triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next","status":"publish","type":"post","link":"https:\/\/massivebio.com\/triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next\/","title":{"rendered":"Triple-Negative Breast Cancer Treatment: Why It\u2019s Harder to Treat and What\u2019s Next"},"content":{"rendered":"<section class=\"l-section wpb_row height_small\"><div class=\"l-section-h i-cf\"><div class=\"g-cols vc_row via_grid cols_1 laptops-cols_inherit tablets-cols_inherit mobiles-cols_1 valign_top type_default stacking_default\"><div class=\"wpb_column vc_column_container\"><div class=\"vc_column-inner\"><div class=\"wpb_text_column\"><div class=\"wpb_wrapper\"><h2><span style=\"font-weight: 400;\">Triple-Negative Breast Cancer Treatment: Why It\u2019s Harder to Treat and What\u2019s Next<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">Triple-negative breast cancer (TNBC), which comprises about 10-15% of breast cancer diagnoses, is an aggressive and complex form distinguished by the absence of estrogen receptors (ER), progesterone receptors (PR), and HER2 protein. This absence makes TNBC unresponsive to many effective hormone and targeted therapies used in other breast cancer types.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Making up roughly 10\u201315% of breast cancer diagnoses, TNBC is distinguished by its aggressive and challenging behavior. So, <\/span><b>\u201cWhat is TNBC and why is it a difficult indication to treat?\u201d<\/b><span style=\"font-weight: 400;\"> is crucial. Triple-negative breast cancer lacks estrogen, progesterone, and HER2 receptors. This lack of receptors means TNBC does not respond to many effective hormone-based and targeted therapies commonly used in other breast cancer types, making it particularly challenging to manage.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">What Is TNBC and Why Is It a Difficult Indication to Treat?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">TNBC is an aggressive breast cancer that lacks hormone and HER2 receptors, making standard targeted treatments ineffective and treatment more challenging. To understand why <\/span><b>treatment for triple negative breast cancer<\/b><span style=\"font-weight: 400;\"> is so complex, the first question to be answered is: \u201c<\/span><b>What is TNBC treatment?\u201d<\/b><span style=\"font-weight: 400;\"> and how is it different?<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">What Makes TNBC Unique?<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">TNBC doesn\u2019t rely on hormones or HER2 to grow, setting it apart from other breast cancers and making it more aggressive, with features such as:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Faster tumor growth<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A higher likelihood of recurrence<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A tendency to spread (metastasize) earlier and more frequently<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Because standard treatments like hormone therapy (e.g., tamoxifen) or HER2-targeted therapy (e.g., trastuzumab) are ineffective, <\/span><b>TNBC treatment options<\/b><span style=\"font-weight: 400;\"> have traditionally relied heavily on chemotherapy.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Moreover, TNBC disproportionately affects younger women, Black women, and those with BRCA1 gene mutations\u2014making personalized treatment even more essential.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">Why Do Treatment Approaches Differ In Triple Negative Breast Cancer?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">How <\/span><a href=\"https:\/\/massivebio.com\/triple-negative-breast-cancer\/\"><span style=\"font-weight: 400;\">triple negative breast cancer<\/span><\/a><span style=\"font-weight: 400;\"> is treated depends on a variety of factors, including cancer stage, tumor size, lymph node involvement, genetic mutations, and the patient\u2019s overall health. This question <\/span><b>\u201cWhat is the best treatment for triple-negative breast cancer?\u201d <\/b><span style=\"font-weight: 400;\">is curious. Here&#8217;s what the <\/span><b>TNBC treatment guidelines<\/b><span style=\"font-weight: 400;\"> typically recommend:\u00a0<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Early Stage: Stage 1 TNBC Treatment<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">For <\/span><b>stage 1 TNBC treatment<\/b><span style=\"font-weight: 400;\">, when the tumor is localized and hasn&#8217;t reached the lymph nodes:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">The first step in <\/span><b>triple negative breast cancer treatment options <\/b><span style=\"font-weight: 400;\">often involves surgery, which may be a lumpectomy or mastectomy.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Post-surgery, chemotherapy is usually recommended to lower the risk of recurrence.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Radiation therapy may sometimes be administered afterward, particularly following a lumpectomy.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Early-stage TNBC is limited to a specific area, allowing for better outcomes if caught early, yet it still has a higher likelihood of coming back compared to other breast cancer subtypes.<\/span><\/p>\n<h2><\/h2>\n<h3><span style=\"font-weight: 400;\">Chemotherapy as the Backbone<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Chemotherapy is the cornerstone of treatment for triple-negative breast cancer at every stage. While effective at targeting rapidly dividing cells, it often causes considerable side effects. Common treatment plans include:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Anthracyclines (e.g., doxorubicin)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Taxanes (e.g., paclitaxel)<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Platinum-based drugs (e.g., carboplatin)<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">In many cases, neoadjuvant chemotherapy\u2014given before surgery\u2014is used to shrink tumors and assess how well the cancer responds.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">What Are the Latest Treatments for Triple-Negative Breast Cancer?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">The latest treatments for triple-negative breast cancer include immunotherapy with checkpoint inhibitors, PARP inhibitors for BRCA-mutated cases, and targeted antibody-drug conjugates like sacituzumab govitecan. In recent years, expanding treatment choices for triple-negative breast cancer beyond chemotherapy has gained momentum. Here\u2019s an overview of the available options.<\/span><\/p>\n<h3><span style=\"font-weight: 400;\">Immunotherapy<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Immunotherapy has emerged as one of the most promising advances in TNBC treatment. Drugs like atezolizumab and pembrolizumab, classified as checkpoint inhibitors, assist the immune system in spotting and attacking cancer cells.<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Often applied in metastatic TNBC, these therapies may also be paired with chemotherapy during earlier phases of the disease.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Testing for PD-L1 expression helps determine whether immunotherapy is appropriate.<\/span><\/li>\n<\/ul>\n<h3><span style=\"font-weight: 400;\">Using PARP Inhibitors to Treat BRCA-Related Cancers<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">For those with BRCA1 or BRCA2 gene mutations, PARP inhibitors like olaparib offer a targeted option. These medications prevent cancer cells from fixing damaged DNA, resulting in their destruction.<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Especially useful for advanced TNBC and maintenance therapy after chemotherapy.<\/span><\/li>\n<\/ul>\n<h3><span style=\"font-weight: 400;\">Targeted Therapy: Antibody-Drug Conjugates<\/span><\/h3>\n<p><span style=\"font-weight: 400;\">Sacituzumab govitecan is a newer drug that combines chemotherapy with a monoclonal antibody to specifically target cancer cells. Approved by the FDA for use in metastatic TNBC, it has delivered strong results in clinical studies.<\/span><\/p>\n<h2><span style=\"font-weight: 400;\">What Are The Challenges In TNBC Treatment And Why Is It Still Harder To Treat?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">TNBC treatment is challenging due to the lack of targetable receptors, high and aggressive recurrence rates, limited duration of response to new therapies, and significant variability among TNBC subtypes. The question <\/span><b>\u201cHow to treat triple negative breast cancer?\u201d<\/b><span style=\"font-weight: 400;\"> is important. Despite progress, triple-negative breast cancer remains challenging to treat:<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Lack of Targetable Receptors: As mentioned earlier, TNBC lacks ER, PR, and HER2, leaving fewer molecular &#8220;hooks&#8221; for targeted therapy. This limits <\/span><a href=\"https:\/\/massivebio.com\/solutions\/\"><span style=\"font-weight: 400;\">solutions <\/span><\/a><span style=\"font-weight: 400;\">and forces reliance on more generalized, often toxic treatments.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">High Recurrence Rates: TNBC is more likely to recur early and aggressively, typically within three years post-treatment, and is more difficult to control after it returns.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Limited Response Duration: While drugs like immunotherapy and PARP inhibitors offer hope, their benefits may not be long-lasting for all patients. Many eventually develop resistance.<\/span><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Individual Variability: Not all TNBCs behave the same way. Researchers now believe there are subtypes within TNBC, each with different characteristics. Until these are better understood, one-size-fits-all treatment will continue to fall short.<\/span><\/li>\n<\/ul>\n<h2><span style=\"font-weight: 400;\">What Are The Newest Treatment Options For Triple-Negative Breast Cancer?<\/span><\/h2>\n<p><span style=\"font-weight: 400;\">The latest TNBC treatments include personalized medicine, new immunotherapy combos, advanced antibody-drug conjugates, and maintenance therapies to prevent recurrence. So, <\/span><b>\u201cWhat is the latest treatment for triple-negative breast cancer?\u201d<\/b><span style=\"font-weight: 400;\">, and what can patients expect in the near future?<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Personalized Medicine: Emerging trials are focusing on tumor profiling and genomic testing to better match patients with the right therapies. Molecular markers such as androgen receptors, immune signatures, and PIK3CA mutations are under active investigation.<\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">New Immunotherapy Combinations: Researchers are testing combinations of checkpoint inhibitors, cancer vaccines, and oncolytic viruses to make immune therapies more effective.<\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Expanded Use of Antibody-Drug Conjugates: Beyond sacituzumab govitecan, new drugs like datopotamab deruxtecan are showing early promise in <\/span><a href=\"https:\/\/massivebio.com\/triple-negative-breast-cancer-clinical-trials\/\"><span style=\"font-weight: 400;\">triple negative breast cancer clinical trials<\/span><\/a><span style=\"font-weight: 400;\"> and may offer additional options in coming years.<\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Prevention of Recurrence: Trials are ongoing to test maintenance therapy\u2014less intense treatments given after chemotherapy\u2014to keep cancer from returning. Drugs like capecitabine and PARP inhibitors are part of this approach.<\/span><\/li>\n<\/ul>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Inclusion of Younger and Minority Women in Trials: Since TNBC disproportionately affects younger and African American women, efforts are being made to diversify clinical trials, ensuring the newest therapies work across all populations.<\/span><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">Treating triple-negative breast cancer is undoubtedly more difficult than other forms of the disease, but it is far from hopeless. While TNBC lacks the traditional hormonal and HER2 targets, new <\/span><b>triple negative breast cancer treatment guidelines <\/b><span style=\"font-weight: 400;\">reflect a growing list of options\u2014including immunotherapy, targeted therapies, and innovative drug combinations.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">From stage 1 <\/span><b>TNBC treatment <\/b><span style=\"font-weight: 400;\">to managing metastatic disease, the key is a personalized, multi-disciplinary approach. If you or a loved one is facing this diagnosis, stay informed, ask about clinical trials, and work with a care team experienced in <\/span><b>triple negative breast cancer treatment<\/b><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">With continued research and advocacy, the outlook for TNBC patients is steadily improving\u2014and the future holds real promise for turning this aggressive cancer into a manageable condition. Combining AI technology with customized care, Massive Bio helps patients throughout all phases of cancer treatment.<\/span><\/p>\n<\/div><\/div><\/div><\/div><\/div><\/div><\/section>\n","protected":false},"excerpt":{"rendered":"Triple-Negative Breast Cancer Treatment: Why It\u2019s Harder to Treat and What\u2019s Next Triple-negative breast cancer (TNBC), which comprises about 10-15% of breast cancer diagnoses, is an aggressive and complex form distinguished by the absence of estrogen receptors (ER), progesterone receptors (PR), and HER2 protein. This absence makes TNBC unresponsive to many effective hormone and targeted...","protected":false},"author":11,"featured_media":36332,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[57],"tags":[],"class_list":["post-36331","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.6 (Yoast SEO v26.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Triple-Negative Breast Cancer Treatment: Why It\u2019s Harder to Treat and What\u2019s Next<\/title>\n<meta name=\"description\" content=\"Triple-negative breast cancer (TNBC), which comprises about 10-15% of breast cancer diagnoses, is an aggressive and complex form distinguished by the absence of estrogen receptors (ER), progesterone receptors (PR), and HER2 protein.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/massivebio.com\/triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Triple-Negative Breast Cancer Treatment: Why It\u2019s Harder to Treat and What\u2019s Next %\" \/>\n<meta property=\"og:description\" content=\"Triple-negative breast cancer (TNBC), which comprises about 10-15% of breast cancer diagnoses, is an aggressive and complex form distinguished by the absence of estrogen receptors (ER), progesterone receptors (PR), and HER2 protein.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/massivebio.com\/triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next\/\" \/>\n<meta property=\"og:site_name\" content=\"Massive Bio\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-22T12:13:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/07\/Triple-Negative-Breast-Cancer-Treatment_-Why-Its-Harder-to-Treat-and-Whats-Next-4.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"767\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sinan Gul\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MassiveBio\" \/>\n<meta name=\"twitter:site\" content=\"@MassiveBio\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sinan Gul\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Triple-Negative Breast Cancer Treatment: Why It\u2019s Harder to Treat and What\u2019s Next","description":"Triple-negative breast cancer (TNBC), which comprises about 10-15% of breast cancer diagnoses, is an aggressive and complex form distinguished by the absence of estrogen receptors (ER), progesterone receptors (PR), and HER2 protein.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/massivebio.com\/triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next\/","og_locale":"en_US","og_type":"article","og_title":"Triple-Negative Breast Cancer Treatment: Why It\u2019s Harder to Treat and What\u2019s Next %","og_description":"Triple-negative breast cancer (TNBC), which comprises about 10-15% of breast cancer diagnoses, is an aggressive and complex form distinguished by the absence of estrogen receptors (ER), progesterone receptors (PR), and HER2 protein.","og_url":"https:\/\/massivebio.com\/triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next\/","og_site_name":"Massive Bio","article_publisher":"https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/","article_published_time":"2025-07-22T12:13:02+00:00","og_image":[{"width":1024,"height":767,"url":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/07\/Triple-Negative-Breast-Cancer-Treatment_-Why-Its-Harder-to-Treat-and-Whats-Next-4.webp","type":"image\/webp"}],"author":"Sinan Gul","twitter_card":"summary_large_image","twitter_creator":"@MassiveBio","twitter_site":"@MassiveBio","twitter_misc":{"Written by":"Sinan Gul","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/massivebio.com\/triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next\/#article","isPartOf":{"@id":"https:\/\/massivebio.com\/triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next\/"},"author":{"name":"Sinan Gul","@id":"https:\/\/massivebio.com\/#\/schema\/person\/961d749445523a588f7ffb7086d037c6"},"headline":"Triple-Negative Breast Cancer Treatment: Why It\u2019s Harder to Treat and What\u2019s Next","datePublished":"2025-07-22T12:13:02+00:00","mainEntityOfPage":{"@id":"https:\/\/massivebio.com\/triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next\/"},"wordCount":1261,"commentCount":0,"publisher":{"@id":"https:\/\/massivebio.com\/#organization"},"image":{"@id":"https:\/\/massivebio.com\/triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next\/#primaryimage"},"thumbnailUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/07\/Triple-Negative-Breast-Cancer-Treatment_-Why-Its-Harder-to-Treat-and-Whats-Next-4.webp","articleSection":["Blog"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/massivebio.com\/triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/massivebio.com\/triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next\/","url":"https:\/\/massivebio.com\/triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next\/","name":"Triple-Negative Breast Cancer Treatment: Why It\u2019s Harder to Treat and What\u2019s Next","isPartOf":{"@id":"https:\/\/massivebio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/massivebio.com\/triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next\/#primaryimage"},"image":{"@id":"https:\/\/massivebio.com\/triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next\/#primaryimage"},"thumbnailUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/07\/Triple-Negative-Breast-Cancer-Treatment_-Why-Its-Harder-to-Treat-and-Whats-Next-4.webp","datePublished":"2025-07-22T12:13:02+00:00","description":"Triple-negative breast cancer (TNBC), which comprises about 10-15% of breast cancer diagnoses, is an aggressive and complex form distinguished by the absence of estrogen receptors (ER), progesterone receptors (PR), and HER2 protein.","breadcrumb":{"@id":"https:\/\/massivebio.com\/triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/massivebio.com\/triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/massivebio.com\/triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next\/#primaryimage","url":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/07\/Triple-Negative-Breast-Cancer-Treatment_-Why-Its-Harder-to-Treat-and-Whats-Next-4.webp","contentUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/07\/Triple-Negative-Breast-Cancer-Treatment_-Why-Its-Harder-to-Treat-and-Whats-Next-4.webp","width":1024,"height":767,"caption":"Triple Negative Breast Cancer Treatment Why Its Harder to Treat and Whats Next 4"},{"@type":"BreadcrumbList","@id":"https:\/\/massivebio.com\/triple-negative-breast-cancer-treatment-why-its-harder-to-treat-and-whats-next\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Homepage","item":"https:\/\/massivebio.com\/"},{"@type":"ListItem","position":2,"name":"Blog","item":"https:\/\/massivebio.com\/blog-en\/"},{"@type":"ListItem","position":3,"name":"Triple-Negative Breast Cancer Treatment: Why It\u2019s Harder to Treat and What\u2019s Next"}]},{"@type":"WebSite","@id":"https:\/\/massivebio.com\/#website","url":"https:\/\/massivebio.com\/","name":"Cancer Analysis and Clinical Trial Matching","description":"Best Oncology Advisory Services By Cancer Treatment Care Specialists &amp; Tumor Board Experts in America","publisher":{"@id":"https:\/\/massivebio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/massivebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/massivebio.com\/#organization","name":"Massive Bio","url":"https:\/\/massivebio.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/massivebio.com\/#\/schema\/logo\/image\/","url":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/01\/Massive-Bio-Logo-Circle.svg","contentUrl":"https:\/\/massivebio.com\/wp-content\/uploads\/2025\/01\/Massive-Bio-Logo-Circle.svg","width":"1024","height":"1024","caption":"Massive Bio"},"image":{"@id":"https:\/\/massivebio.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/facebook.com\/people\/Massive-Bio-As\/100094663612187\/","https:\/\/x.com\/MassiveBio","https:\/\/instagram.com\/massive_bio\/","https:\/\/tiktok.com\/@massivebio","https:\/\/youtube.com\/massivebio"],"email":"support@massivebio.com","legalName":"Massive Bio"},{"@type":"Person","@id":"https:\/\/massivebio.com\/#\/schema\/person\/961d749445523a588f7ffb7086d037c6","name":"Sinan Gul"}]}},"_links":{"self":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/36331","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/comments?post=36331"}],"version-history":[{"count":1,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/36331\/revisions"}],"predecessor-version":[{"id":36333,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/posts\/36331\/revisions\/36333"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/media\/36332"}],"wp:attachment":[{"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/media?parent=36331"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/categories?post=36331"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/massivebio.com\/wp-json\/wp\/v2\/tags?post=36331"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}